A survey released today by the Healthcare Distribution Alliance (HDA) Research Foundation indicates the pharmaceutical supply chain continues to make steady progress to comply with the 2013 Drug Supply Chain Security Act (DSCSA); however, some implementation priorities have shifted amid the initial industry response to the COVID-19 pandemic.
A report published by the Healthcare Distribution Alliance (HDA) Research Foundation and Deloitte Consulting LLP found that during the first 90 days of the COVID-19 pandemic, the biopharmaceutical finished goods industry quickly adapted and adjusted to deliver medicines safely and efficiently to patients, with only minimal disruptions.
In response to the Food and Drug Administration’s (FDA) decision to extend enforcement discretion related to certain Drug Supply Chain Security Act requirements, the Healthcare Distribution Alliance (HDA) released the following statement.
The Healthcare Distribution Alliance (HDA) today released policy principles reaffirming the pharmaceutical distribution industry’s commitment to ensuring — in partnership with federal and state governments — the safe and efficient distribution of COVID-19 vaccines once they are approved by the Food and Drug Administration.
HDA’s Pharmaceutical Cargo Security Coalition recognized three outstanding supply chain security professionals today through the annual PCSC Awards.
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269
